These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

56 related items for PubMed ID: 2701743

  • 1. Plasma proteinase regulation during disease progression in murine models of SLE.
    Hart DA, Garlepp M, Fritzler M.
    J Clin Lab Immunol; 1989 Sep; 30(1):27-34. PubMed ID: 2701743
    [Abstract] [Full Text] [Related]

  • 2. Regulation of plasma complement C4 and factor b levels in murine systemic lupus erythematosus.
    Garlepp MJ, Hart DA, Fritzler MJ.
    J Clin Lab Immunol; 1989 Mar; 28(3):137-41. PubMed ID: 2738911
    [Abstract] [Full Text] [Related]

  • 3. Influence of biological response modifiers of bacterial origin on disease progression in the MRL-lpr model of systemic lupus erythematosus.
    Hart DA, Krause G, Martin L, Garlepp M, Fritzler MJ.
    Clin Invest Med; 1991 Feb; 14(1):55-62. PubMed ID: 2040105
    [Abstract] [Full Text] [Related]

  • 4. Resistance to tolerance induction is not prerequisite to development of murine SLE.
    Izui S, Masuda K.
    J Immunol; 1984 Dec; 133(6):3010-4. PubMed ID: 6491280
    [Abstract] [Full Text] [Related]

  • 5. Oncogene expression in autoimmune mice.
    Mountz JD, Mushinski JF, Mark GE, Steinberg AD.
    J Mol Cell Immunol; 1985 Dec; 2(3):121-31. PubMed ID: 3916923
    [Abstract] [Full Text] [Related]

  • 6. Genetic basis of murine lupus.
    Santiago-Raber ML, Laporte C, Reininger L, Izui S.
    Autoimmun Rev; 2004 Jan; 3(1):33-9. PubMed ID: 14871647
    [Abstract] [Full Text] [Related]

  • 7. Abrogation of skin disease in LUPUS-prone MRL/FASlpr mice by means of a novel tylophorine analog.
    Choi JY, Gao W, Odegard J, Shiah HS, Kashgarian M, McNiff JM, Baker DC, Cheng YC, Craft J.
    Arthritis Rheum; 2006 Oct; 54(10):3277-83. PubMed ID: 17009262
    [Abstract] [Full Text] [Related]

  • 8. MRL mice produce anti-Su autoantibody, a specificity associated with systemic lupus erythematosus.
    Treadwell EL, Cohen P, Williams D, O'Brien K, Volkman A, Eisenberg R.
    J Immunol; 1993 Jan 15; 150(2):695-9. PubMed ID: 8419494
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of lupus disease by anti-double-stranded DNA antibodies of the IgM isotype in the (NZB x NZW)F1 mouse.
    Werwitzke S, Trick D, Kamino K, Matthias T, Kniesch K, Schlegelberger B, Schmidt RE, Witte T.
    Arthritis Rheum; 2005 Nov 15; 52(11):3629-38. PubMed ID: 16255055
    [Abstract] [Full Text] [Related]

  • 10. Immunological abnormalities in BXSB mice at the onset of SLE development.
    Morrison LJ, Menzies CB, Behan WM, Behan PO.
    J Clin Lab Immunol; 1990 May 15; 32(1):5-11. PubMed ID: 1967037
    [Abstract] [Full Text] [Related]

  • 11. Genomic view of IFN-alpha response in pre-autoimmune NZB/W and MRL/lpr mice.
    Lu Q, Shen N, Li XM, Chen SL.
    Genes Immun; 2007 Oct 15; 8(7):590-603. PubMed ID: 17728792
    [Abstract] [Full Text] [Related]

  • 12. Glatiramer acetate treatment does not modify the clinical course of (NZB x BXSB)F1 lupus murine model.
    Borel P, Benkhoucha M, Weber MS, Zamvil SS, Santiago-Raber ML, Lalive PH.
    Int Immunol; 2008 Oct 15; 20(10):1313-9. PubMed ID: 18687587
    [Abstract] [Full Text] [Related]

  • 13. The effect of thymectomy on lupus-prone mice.
    Hang L, Theofilopoulos AN, Balderas RS, Francis SJ, Dixon FJ.
    J Immunol; 1984 Apr 15; 132(4):1809-13. PubMed ID: 6142069
    [Abstract] [Full Text] [Related]

  • 14. Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32).
    Werwitzke S, Trick D, Sondermann P, Kamino K, Schlegelberger B, Kniesch K, Tiede A, Jacob U, Schmidt RE, Witte T.
    Ann Rheum Dis; 2008 Feb 15; 67(2):154-61. PubMed ID: 17557887
    [Abstract] [Full Text] [Related]

  • 15. Plasma levels of nucleosomes and nucleosome-autoantibody complexes in murine lupus: effects of disease progression and lipopolyssacharide administration.
    Licht R, van Bruggen MC, Oppers-Walgreen B, Rijke TP, Berden JH.
    Arthritis Rheum; 2001 Jun 15; 44(6):1320-30. PubMed ID: 11407691
    [Abstract] [Full Text] [Related]

  • 16. Distinct clonotypes of anti-DNA antibodies in mice with lupus nephritis.
    Yoshida H, Yoshida M, Izui S, Lambert PH.
    J Clin Invest; 1985 Aug 15; 76(2):685-94. PubMed ID: 3875630
    [Abstract] [Full Text] [Related]

  • 17. Responses of B cells from autoimmune mice to IL-5.
    Umland SP, Go NF, Cupp JE, Howard M.
    J Immunol; 1989 Mar 01; 142(5):1528-35. PubMed ID: 2783944
    [Abstract] [Full Text] [Related]

  • 18. Splenic norepinephrine is decreased in MRL-lpr/lpr mice.
    Breneman SM, Moynihan JA, Grota LJ, Felten DL, Felten SY.
    Brain Behav Immun; 1993 Jun 01; 7(2):135-43. PubMed ID: 8347895
    [Abstract] [Full Text] [Related]

  • 19. Studies on the mechanisms of the development of lupus nephritis in BXSB mice. II. Comparative studies between male BXSB and MRL/lpr mice at the onset period.
    Makino M, Fujiwara M, Watanabe H.
    J Clin Lab Immunol; 1988 Feb 01; 25(2):83-8. PubMed ID: 3259631
    [Abstract] [Full Text] [Related]

  • 20. CXCR3 mediates renal Th1 and Th17 immune response in murine lupus nephritis.
    Steinmetz OM, Turner JE, Paust HJ, Lindner M, Peters A, Heiss K, Velden J, Hopfer H, Fehr S, Krieger T, Meyer-Schwesinger C, Meyer TN, Helmchen U, Mittrücker HW, Stahl RA, Panzer U.
    J Immunol; 2009 Oct 01; 183(7):4693-704. PubMed ID: 19734217
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.